NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

I'm guessing around $70K on average, but it could be less and still quite profitable for NW. I think patient #'s will only be limited to manufacturing capacity in Germany. It's likely that much of the money raised has gone to increasing both capacity itself (beyond the 8,000 sq.ft. facility they have some production in) and the ability to front costs of actual vaccine production (COGS).

Let's say they have managed to increase capacity to produce vaccine for 300 patients/yr at this time (beyond the Ph III trial), and have the cash to produce that many vaccines for HE. I think they will be able to meet that target, and before the year is up, have increased capacity to perhaps double this.

I think their one year target will be 300-500 patients, $50k-$70k/tx. Then second year target around 1,000 patients, etc. COGS initially around $30k, then dropping to $16k once fully operational. And maybe.. just maybe, some rather large non-dilutive financing comes in from a financial group (9-figures) and things really get interesting.

And I am wildly speculating lol